Linezolid is an oxazolidinone antibiotic whose mechanism of action is to inhibit bacterial protein synthesis. Therefore, the action of linezolid is also different from traditional antibacterial drugs, for Gram-positive bacteria, drug-resistant bacteria, the same inhibitory, bactericidal effect, thus reducing the emergence of drug-resistant bacteria. Clinically, for the treatment of methicillin-resistant Aureus infections, it is similar to vancomycin or even higher than vancomycin in terms of cure rate and clearance rate, making it an effective drug for the treatment of methicillin-resistant Aureus. Clinically, with the increasing detection rate of methicillin-resistant S. aureus, the large number of applications of glycopeptide antibiotics has also led to a decrease in the sensitivity of such drugs for methicillin-resistant S. aureus. Therefore, the use of linezolid in the treatment of methicillin-resistant S. aureus can be an alternative to glycopeptide resistance.